TB-500 solves a different problem than BPC-157. Where BPC-157 drives local repair at the injury site, TB-500 coordinates the logistics: getting the right cells to the right place and organizing them into functional architecture rather than scar tissue. It maintains a reserve pool of structural building blocks (G-actin monomers) inside cells, enabling rapid deployment when repair demands it. Cells that were stuck start moving. Chaotic scar starts organizing.
TB-4 — the parent molecule — has Phase 1 human safety data (84 healthy volunteers, doses up to 25 μg/kg daily for 10 days, no serious adverse events⁷) and Phase 3 efficacy data in corneal wound healing. Thymosin beta-4 is among the most conserved peptides across species, nearly identical from fish to mammals — suggesting an ancient and fundamental role in tissue repair.
Where TB-500 wins: large-area tissue damage, injuries with multiple affected sites, and the Wolverine Stack pairing where both mechanisms compound. An important distinction: TB-500 is a 7-amino-acid fragment of thymosin beta-4, engineered as the concentrated active region for tissue repair — but most products labeled "TB-500" actually contain full-length TB-4 (43 amino acids). Both work; the difference matters mainly for injection routing. Effects are slower than BPC-157 — morning stiffness decreases in weeks 1–2, but load tolerance improvements arrive through weeks 5–8.
| At a Glance | |
|---|---|
| Dosage | 2–4 mg subcutaneous or intramuscular, 2–4× per week during loading, 1–2× per week for maintenance. |
| Protocol | Loading: 4–8 mg/week split across 2–4 doses for 4 weeks. Maintenance: 2–4 mg/week for weeks 5–8. SubQ near injury site when possible. |
| Results timeline | Morning stiffness and first-step pain decrease within weeks 1–2, range of motion improves by weeks 3–4, and load tolerance increases through weeks 5–8. |
| Side effects | Occasional injection site reactions and rare mild lethargy lasting 12–24 hours — Phase 1 trials showed safety at doses approximately 100-fold higher than standard protocols. |
| Regulatory status | Research peptide, not FDA-approved. WADA prohibited (S0). |
| Best stacked with | BPC-157 — see Wolverine Stack. GHK-Cu, KPV for collagen quality and inflammation control. |
What TB-500 Is
Thymosin beta-4 (TB-4) is a 43-amino-acid protein first isolated from the thymus gland in the 1960s, but subsequent research found it everywhere: platelets, wound fluid, developing tissue, regenerating muscle. It is among the most conserved peptides across species — the human version is nearly identical to versions found in fish, amphibians, and mammals — suggesting an ancient and fundamental role in tissue repair.
TB-500 is a 7-amino-acid fragment (positions 17–23, sequence LKKTETQ) of that parent molecule — the specific region responsible for actin binding and cell migration. It was isolated because this short sequence concentrates the tissue repair activity of the full protein into a smaller, synthetically simpler compound (~800 Da vs ~4,900 Da for full-length TB-4).
The naming problem: Most vendors selling "TB-500" are actually selling full-length TB-4. Doping control analysis of commercial products confirmed this directly — vials labeled "TB-500" contained the full 43-amino-acid protein¹³. The fragment is harder to synthesize and less commercially available. Both have tissue repair activity — TB-4 contains the same active region plus additional sequence — but they are not the same compound. Check the Certificate of Analysis: if molecular weight is ~4,900 Da, you have TB-4 regardless of label. See the FAQ below for how to verify.
This guide uses "TB-500" to refer to the fragment and "TB-4" for the full molecule. The dosing protocols work for either, but they are not mechanistically identical — TB-4 carries active sites that the fragment does not (see How It Works). Knowing which you have matters for what effects you can expect and for injection routing (see Dosing).
Unlike growth factors that primarily instruct cells to proliferate, TB-500 orchestrates where cells go and how they arrange themselves once they arrive. Addressing this second bottleneck — cellular choreography — is what distinguishes TB-500 from most other repair compounds.
How TB-500 Works
TB-500 and TB-4 share the actin-binding domain, but they're not mechanistically identical. TB-4 carries active sites the fragment doesn't — most importantly an anti-fibrotic fragment (Ac-SDKP) that TB-500 lacks entirely. Where it matters, the distinction is noted below.
Enables rapid cell migration
Inside every cell, actin proteins form the structural scaffolding that enables movement and division. Actin exists in two states: monomers (G-actin) floating freely in the cytoplasm, and filaments (F-actin) assembled into functional structures.
The LKKTETQ sequence — present in both TB-500 and TB-4 — binds G-actin monomers, preventing premature assembly into filaments (actin sequestration¹). This creates a reserve pool that cells can rapidly deploy when they need to move, divide, or reorganize. Without this reserve, cells respond sluggishly to repair signals — they have to manufacture new actin rather than drawing from inventory.
The practical result: fibroblasts migrate efficiently into injured tendons. Endothelial cells extend into damaged zones to form new blood vessels. Keratinocytes advance across wound surfaces. In each case, the rate-limiting step shifts from "can the cell move?" to "where should it go?"
A 2024 finding adds nuance: TB-500 undergoes serial C-terminal cleavage after injection, and one of its metabolites — Ac-LKKTE — showed significant wound healing activity in its own right (Yang et al. 2024⁹). TB-500 may function partly as a prodrug, with degradation products contributing to the biological effect. This also helps explain why activity persists well beyond TB-500's short plasma half-life.
Builds new blood vessels
Beyond enabling cell migration generally, fragment 17–23 specifically promotes blood vessel formation. Endothelial cells — the cells lining blood vessels — respond by migrating into injured areas and assembling into tube structures (endothelial migration and tube formation²).
This mechanism complements but differs from BPC-157's approach to angiogenesis. BPC-157 upregulates VEGF (the signal to build vessels); TB-500 enables the endothelial cells to physically move and organize into functional capillaries. The two peptides address different parts of the same process, which is why they combine effectively.
Reduces excessive scarring
This effect comes from TB-4, not the TB-500 fragment. A comprehensive review of TB-4 fragment functions mapped three distinct active sites within the molecule¹⁵ — and anti-fibrotic activity belongs to Ac-SDKP, a 4-amino-acid fragment (positions 1–4) released when TB-4 is enzymatically processed. Ac-SDKP suppresses TGF-beta/Smad2/3 signaling and blocks myofibroblast differentiation — the cells responsible for excessive scar formation³.
This processing requires a two-step enzymatic cascade: meprin-alpha first cuts TB-4 into shorter intermediates, then prolyl oligopeptidase (POP) releases Ac-SDKP from those intermediates (Kumar & Bhatt 2016¹⁰). POP cannot cleave full-length TB-4 directly — the 43-amino-acid protein exceeds its ~30 amino acid structural limit.
In cardiac, hepatic, and renal fibrosis models, TB-4 reduced pathological collagen deposition without impairing necessary tissue repair. TB-500 does not contain the Ac-SDKP sequence and does not produce this anti-fibrotic effect. If scar reduction is a primary goal, TB-4 (the full molecule) is what the evidence supports.
Shifts immune cells toward repair
Immune cells called macrophages play two distinct roles during healing. Early after injury, M1 macrophages drive inflammation — clearing debris, fighting infection, recruiting other immune cells. Later, M2 macrophages promote tissue remodeling — organizing new matrix, resolving inflammation, coordinating repair.
TB-4 promotes the shift from inflammatory M1 toward reparative M2 macrophages (macrophage polarization⁴). This transitions healing from acute inflammation to productive repair. However, this effect has been studied with full-length TB-4, not the isolated 17–23 fragment. Whether TB-500 alone drives macrophage polarization is unknown — it may require the Ac-SDKP fragment or other regions of the full molecule.
Applications
Tendon and Ligament Healing
Stalled healing presents a familiar pattern: tissue feels stiff and tight, range of motion is limited, every attempt to load triggers setbacks. Morning stiffness takes 20+ minutes to resolve. "First-step" pain persists despite time and rest.
This persistent dysfunction reflects failed cell migration and organization. Repair cells can't reach damaged tissue efficiently. Those that arrive don't organize properly. The result: disorganized scar tissue, adhesions between tissue planes, mechanical dysfunction that doesn't resolve on its own.
Physical therapy applies mechanical force but can't fix cellular choreography. Manual therapy temporarily breaks adhesions but doesn't address why cells didn't organize correctly. Surgery creates new trauma without solving the underlying migration failure.
TB-500 addresses the bottleneck directly — enabling cell migration and organization so the repair cascade proceeds through stalled phases.
What to expect:
- Weeks 1-2: Morning stiffness and "first-step" pain decrease
- Weeks 3-4: Range of motion improves, tissue planes separate properly
- Weeks 5-8: Eccentric loading tolerance increases, progressive loading becomes possible
Wound Healing
TB-500 accelerates wound closure through multiple coordinated effects: keratinocytes migrate faster to cover wound surfaces, endothelial cells form new vasculature within the wound bed, fibroblasts deposit collagen in organized patterns rather than chaotic scar.
A trial of 72 patients with chronic venous ulcers found approximately 25% complete wound closure at 3 months using 0.03% thymosin beta-4 gel⁵. While modest by pharmaceutical standards, this represents meaningful improvement in wounds that had resisted conventional treatment.
The preclinical literature is more extensive: accelerated dermal wound closure, enhanced cellular migration, and — critically — organized tissue remodeling rather than scar formation.
Corneal Healing (Most Advanced Human Data)
The cornea provides the clearest human evidence for TB-4 efficacy, precisely because the cornea lacks blood vessels. This eliminates the confound of improved perfusion — any healing effect must come from direct cellular action.
The SEER-1 Phase 3 trial enrolled 18 patients with neurotrophic keratopathy — a condition where corneal nerves are damaged, impairing the healing reflex. Results were striking: 60% (6 of 10) of patients receiving thymosin beta-4 achieved complete corneal healing, compared to 12.5% (1 of 8) on placebo. At Day 43, 50% of treated patients maintained complete healing versus 0% of placebo patients (p=0.0359)⁶.
This matters beyond ophthalmology because it demonstrates that TB-4's healing effects don't depend solely on improved blood flow. The peptide directly enables the cellular migration and organization necessary for tissue repair.
Cardiac Repair (Preclinical)
In mouse models of myocardial ischemia (heart attacks), TB-4 activated signaling pathways that promote cardiac cell migration and survival (integrin-linked kinase pathway³). It also influenced epicardial progenitor cells — a population that contributes to cardiac regeneration.
This application remains preclinical only. But it establishes mechanistic credibility: the same actin-sequestration and cell-migration effects observed in tendons and wounds operate in cardiac tissue.
Dosing
The peptide calculator converts vial concentration to injection volume.
Protocol Table
| Phase | Dose | Frequency | Duration | Rationale |
|---|---|---|---|---|
| Loading | 4-8 mg/week | Split 2-4 doses | 4 weeks | Front-loads during early-to-mid remodeling phases |
| Maintenance | 2-4 mg/week | 1-2 doses | 2-4 weeks | Allows collagen organization to consolidate |
Common Approach
Starting: 2 mg twice weekly (Monday/Thursday) for the first 4 weeks. This provides consistent peptide exposure during the critical early remodeling phases when tissue architecture is being established.
Titration: If response is slow after 2 weeks, increase to 2 mg 3-4 times weekly. Some individuals require higher initial dosing for adequate tissue concentration.
Taper: After week 4, reduce to 2-4 mg total per week. The loading phase drives cell migration; the maintenance phase supports collagen organization and maturation.
Cycle length: 6-8 weeks is standard. Can repeat after a 4-8 week break if injury remains incompletely healed.
Weight-Based Guidance
Approximately 0.04-0.06 mg/kg per dose provides a reference point, though most protocols use fixed dosing within the ranges above.
Route
Subcutaneous (SC) or intramuscular (IM) injection both work effectively. IM may be preferred for deeper musculoskeletal injuries.
Inject near the injury site when possible. For injuries in difficult-to-reach locations (spine, deep hip), abdominal or thigh injection is the practical alternative.
Both TB-500 and TB-4 enter systemic circulation rapidly — they don't "stay local." But therapeutic effect is concentration-dependent: local injection provides a higher initial concentration at the injury before systemic dilution. Multiple studies confirm this matters — free systemic TB-4 produced zero functional improvement at the same total dose as a locally-targeted formulation in cardiac repair¹¹, and sustained local release via scaffold achieved 93% wound closure in diabetic wounds where systemic delivery would dilute below threshold¹². The peptide goes systemic regardless — what matters is the concentration spike at the injury site during the first-pass window.
Why TB-500 Is Not Daily
BPC-157 works at nanogram thresholds — it triggers signaling cascades catalytically, meaning a small amount flips the switch. TB-500 works by mass-action: it physically binds G-actin monomers one-to-one, sequestering them into reserve pools. You need milligram-scale bolus doses to bind enough actin to meaningfully increase the cellular reserve.
Once those reserves are established, the biological effect persists for days even though the peptide itself clears in hours (half-life 0.5–2.1 hours IV⁷). The actin pools don't disappear when TB-500 clears — they remain available until the cell draws on them for migration or division. This is why 2–4 mg doses 2–3 times per week outperform smaller daily doses: peak concentration drives the binding event, and the downstream effect sustains itself between doses.
The 2×/week frequency is practitioner-derived convention that aligns with this mechanism — not a number derived from formal pharmacokinetic modeling. If you're using full-length TB-4 (which most people are), the same logic applies: the active region within TB-4 binds actin the same way.
Loading Phase Rationale
Front-loading during weeks 1-4 is not arbitrary. The early-to-mid healing phases are when tissue architecture is being established — when cells are migrating into injury sites and beginning to organize. Higher peptide concentration during this window maximizes the migration and organization effects. Once the architectural pattern is established, lower maintenance dosing supports the slower consolidation and maturation phases.
Side Effects and Safety
Side Effect Profile
| Effect | Frequency | Management |
|---|---|---|
| Injection site reactions | Occasional | Rotate sites; warm peptide before injection |
| Mild lethargy (12-24 hrs) | Rare | Hydrate; schedule injection before rest day |
TB-500 is generally very well tolerated. Side effects are mild and infrequent at standard dosing.
Phase 1 Human Safety Data
The most reassuring safety data comes from the Phase 1 trial of recombinant thymosin beta-4 (Wang et al. 2021): 84 healthy volunteers across single-dose (54 subjects, up to 25 μg/kg) and multiple-dose (30 subjects, up to 5 μg/kg daily for 10 days) arms, with no serious adverse events or dose-limiting toxicity⁷.
An important caveat: this trial used recombinant TB-4 (the full-length protein), not synthetic TB-500 (the fragment). The synthetic TB-500 and TB-4 sold by peptide suppliers have not been independently characterized in formal human safety studies. The Wang et al. data provides the closest available human safety reference, but it is not a direct validation of the products most people are using.
Contraindications
Absolute:
- Active cancer or malignancy within 2 years (TB-500 promotes angiogenesis and cell migration)
- Pregnancy or breastfeeding (insufficient safety data)
- Proliferative retinopathy (angiogenesis may worsen pathology)
- Surgery planned or recent (<2 weeks) (excessive angiogenesis may complicate healing)
Relative (use with medical supervision):
- Concurrent corticosteroid use (steroids oppose tissue repair mechanisms)
- Severe cardiovascular disease
- Active autoimmune conditions
- Therapeutic anticoagulation
Regulatory Status
TB-500 is a research peptide without FDA approval. It is not a controlled substance but cannot be marketed for human therapeutic use in the United States.
WADA prohibits TB-500 for competitive athletes (class S0: Non-Approved Substances). Testing protocols can detect TB-500 metabolites. Athletes subject to anti-doping regulations should not use this peptide.
TB-500 is available through research peptide suppliers and some compounding pharmacies. Quality varies significantly among sources — verify third-party testing and proper storage (refrigerated, protected from light).
Stacking with BPC-157
Why This Combination Works
BPC-157 and TB-500 address different bottlenecks in the healing cascade. Combined, they produce effects neither achieves alone — the Wolverine Stack.
| Compound | What It Does | What You Notice |
|---|---|---|
| BPC-157 | Restores blood flow (VEGF upregulation⁸) | Warmth returns; swelling productive |
| TB-500 | Enables cell migration (actin sequestration¹) | Tissue softens; adhesions remodel |
The synergy: BPC-157 builds the vascular roads. TB-500 directs the repair cells traveling on them.
Without perfusion, cells can migrate but lack nutrients to sustain repair — they arrive at the construction site but have no materials. Without migration, blood supply returns but cells don't reach the injury or organize properly — materials arrive but workers are absent.
Together: perfusion + migration = complete cellular choreography.
Wolverine Stack Protocol
| Compound | Dose | Frequency | Route |
|---|---|---|---|
| BPC-157 | 500-750 mcg | Daily | SC near injury site |
| TB-500 | 2-4 mg | 2x weekly | SC near injury site |
Cycle: 6-8 weeks (TB-500), 8-12 weeks (BPC-157)
See BPC-157 + TB-500 Protocol Guide for complete protocol details, weekly scheduling, and troubleshooting.
Other Stack Options
TB-500 + KPV: When tissue stays inflamed despite repair efforts. KPV silences inflammatory signaling without immunosuppression. Protocol: TB-500 2 mg 2-4x/week + KPV 250-500 mcg daily.
TB-500 + GHK-Cu: When collagen quality and scar appearance matter. GHK-Cu optimizes matrix composition during the remodeling phase. Protocol: Front-load TB-500 weeks 1-8, layer GHK-Cu weeks 3-12+.
TB-500 + NAD+: When energy is an issue during healing. NAD+ supports mitochondrial function for sustained repair work. Protocol: TB-500 as scheduled + NAD+ IM 100-300 mg mid-day.
For complex or chronic injuries that don't respond to the Wolverine Stack alone, see the 5-Compound Injury Protocol.
FAQ
What is the recommended TB-500 dosage and protocol?
TB-500 follows a loading-and-maintenance structure. Loading phase: 4–8 mg per week split into 2–4 injections (commonly 2 mg twice weekly) for the first 4 weeks. Maintenance: 2–4 mg per week in 1–2 injections for weeks 5–8. Standard cycles run 6–8 weeks, followed by a 4–8 week break before repeating if needed. Inject near the injury site when possible — same approach as BPC-157. For hard-to-reach injuries, abdominal or thigh injection works. The two are commonly stacked together in the Wolverine protocol.
What is the typical protocol for TB-500?
A typical TB-500 protocol runs 6–8 weeks total with two distinct phases. Loading phase (weeks 1–4): 2 mg injected twice weekly (Monday/Thursday), increasing to 3–4 times weekly if response is slow. Maintenance phase (weeks 5–8): reduce to 2 mg once or twice weekly. Inject near the injury site when possible; abdominal or thigh injection for hard-to-reach injuries. Assess at week 4 to decide whether to continue. If stacking with BPC-157, start both simultaneously but plan for TB-500 to end first.
Does TB-500 need to be cycled or can I take it continuously?
Yes — TB-500 should be cycled. Standard protocol is 6–8 weeks on, followed by 4–8 weeks off before repeating if needed. The cycling structure allows you to assess whether the peptide is contributing to recovery and prevents unnecessary prolonged use. TB-500 is a repair signal, not a maintenance compound — once tissue remodeling is underway, continued dosing has diminishing returns.
What is the difference between TB-500 and TB-4?
TB-500 was originally defined as thymosin beta-4 fragment 17-23 — a 7-amino-acid active fragment with approximately 800 Da molecular weight.
TB-4 is the full-length 43-amino-acid thymosin beta-4 protein with approximately 4,900 Da molecular weight.
The practical reality: Most vendors selling "TB-500" are actually selling full TB-4. The fragment is harder to synthesize and less commercially available. Both have tissue repair activity, but they are not the same compound.
How to verify: Check the Certificate of Analysis (COA). If molecular weight is approximately 4,900 Da or the COA lists 43 amino acids, you have TB-4 regardless of label. If molecular weight is approximately 800 Da, you have the fragment.
Does it matter? Yes — they share the actin-binding mechanism but TB-4 carries active sites the fragment does not:
- TB-500 (fragment): Contains only the actin-binding domain (LKKTETQ). Drives cell migration and angiogenesis. Higher actin-binding activity per milligram because the entire molecule IS the active region. N-terminal acetylation provides metabolic stability. May function partly as a prodrug — the metabolite Ac-LKKTE showed independent wound healing activity⁹.
- TB-4 (full-length): Contains the same actin-binding region PLUS additional active sites. Fragment 1–4 (Ac-SDKP) is released by enzymatic processing and provides anti-fibrotic and anti-inflammatory effects that TB-500 cannot. Fragment 1–15 has anti-apoptotic activity. TB-4 also activates ILK/PINCH/Akt signaling and induces genes including MMPs and TGF-beta. This is what most clinical research uses.
Both molecules enter systemic circulation rapidly after subQ injection — at 800 Da and 4,900 Da respectively, both are well below the ~16 kDa threshold for lymphatic absorption and diffuse directly into blood capillaries. Neither "stays local" at the injection site.
In practice, most people have TB-4 labeled as TB-500 — and that's fine. The dosing protocols in this guide work for either. If your injury involves significant scar tissue or chronic inflammation, TB-4 (with its Ac-SDKP anti-fibrotic fragment) may be the better choice. If pure cell migration and angiogenesis is the bottleneck, TB-500 covers that directly.
How long does TB-500 take to work?
- Weeks 1-2: Stiffness improves, "first-step" pain decreases
- Weeks 3-4: Range of motion increases, tissue planes separate properly
- Weeks 5-8: Can progress to heavier loading without setbacks
Acute injuries respond faster. Chronic issues that have been present for months or years may need full 6-8 week courses, and often benefit from the combination with BPC-157.
Can TB-500 help old injuries?
Yes. TB-500 remains effective even months or years post-injury. Chronic injuries often have multiple stalled bottlenecks — TB-500 addresses the cell migration and organization piece. Complete resolution of long-standing injuries may require adding BPC-157 (perfusion), KPV (inflammation), or GHK-Cu (collagen quality).
Where to inject TB-500
Near the injury site when possible. IM injection may be preferred for deeper musculoskeletal injuries. For hard-to-reach locations (spine, deep hip), abdominal or thigh injection is the practical alternative.
The peptide doesn't "stay local" — it enters systemic circulation rapidly. But therapeutic effect is concentration-dependent, and local injection provides a higher first-pass concentration at the injury before dilution¹¹.
How long is a TB-500 cycle?
Typical course: 6-8 weeks (4 weeks loading + 2-4 weeks maintenance). Can repeat after 4-8 week break if needed. Taper gradually rather than stopping abruptly — this allows collagen organization to consolidate.
Is TB-500 safe?
Phase 1 human data: 84 volunteers tolerated recombinant TB-4 at doses up to 25 μg/kg daily for 10 days with no serious adverse events⁷. This trial used recombinant TB-4, not synthetic TB-500 — the products most people use have not been independently studied in formal trials.
Main precautions: avoid with active cancer (angiogenesis concern), pregnancy, proliferative retinopathy, and peri-operatively (within 2 weeks of surgery).
Is TB-500 legal?
TB-500 is a research peptide without FDA approval. It is not a controlled substance but cannot be marketed for human therapeutic use.
WADA prohibits TB-500 for competitive athletes (class S0: Non-Approved Substances). Testing can detect metabolites. Professional leagues (NFL, NBA, MLB, FIFA) have adopted similar restrictions.
Can I combine TB-500 with BPC-157 in one syringe?
Yes, they are pH compatible. Many clinicians co-inject without issues. If unsure about stability with a specific formulation, use separate syringes.
What if I don't respond to TB-500?
Common factors:
- Insufficient dose: Try increasing to 2 mg 3-4x weekly
- Degraded peptide: Check storage conditions (should be refrigerated, protected from light)
- Missing complementary mechanism: Add BPC-157 for perfusion, KPV for inflammation
- Inadequate time: Chronic injuries may need 8+ weeks
- Underlying structural issue: Consider imaging to rule out mechanical problems requiring different intervention
Related Topics
- BPC-157 + TB-500 Protocol Guide — Complete Wolverine Stack protocol
- Complete BPC-157 Guide — BPC-157 mechanism, dosing, applications
- 5-Compound Injury Protocol — Extended protocol with NAD+, GHK-Cu, KPV
- Peptide Calculator — Calculate injection volumes from vial concentration
- Where to Inject Peptides — Why local injection matters for TB-500's mass-action mechanism
- Reconstitution Guide — How to prepare peptide vials
- GHK-Cu Guide — Copper peptide for matrix quality and scar appearance
- NAD+ Guide — Cellular energy support for energy-intensive healing
- Injury Recovery Protocol — TB-500 in the 3-tier framework with situational additions
- GLOW & KLOW Protocol — Full 5-compound protocol that includes TB-500
References
¹ Actin sequestration mechanism — Thymosin beta-4 binds G-actin monomers, preventing premature polymerization and maintaining reserve pools for rapid cell migration. Goldstein AL et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429. PMID 16099219
² Endothelial migration and tube formation — Thymosin beta-4 promotes angiogenesis by enabling endothelial cell migration and capillary structure formation. Philp D et al. "Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development." Mech Ageing Dev. 2004;125(2):113-115. PMID 15037011
³ Integrin-linked kinase pathway and TGF-beta signaling — Thymosin beta-4 activates ILK, promotes cardiac cell migration and survival, and modulates TGF-beta to reduce fibrosis. Bock-Marquette I et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival, and cardiac repair." Nature. 2004;432(7016):466-472. PMID 15282614
⁴ Macrophage polarization — Thymosin beta-4 promotes shift from pro-inflammatory M1 to reparative M2 macrophage phenotype. Goldstein AL et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-429. PMID 16099219
⁵ Venous ulcer trial — 72 patients across 10 European sites; 0.03% thymosin beta-4 gel produced approximately 25% complete wound closure at 3 months. Treadwell T et al. "Thymosin beta-4 and venous ulcer healing." Ann N Y Acad Sci. 2007. PMID 17495250
⁶ SEER-1 Phase 3 trial — 18 patients with neurotrophic keratopathy; 60% complete corneal healing vs 12.5% placebo; 50% vs 0% maintained healing at Day 43 (p=0.0359). Sosne G et al. "0.1% RGN-259 (Thymosin beta4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: Phase III Clinical Trial." Int J Mol Sci. 2022. PMC9820614
⁷ Phase 1 safety data — 84 healthy volunteers (54 single-dose, 30 multiple-dose) tolerated recombinant thymosin beta-4 at doses up to 25 μg/kg daily for 10 days with no serious adverse events or dose-limiting toxicity. Wang D et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021;9(15):1232. PMC8419156
⁸ BPC-157 angiogenic mechanism — VEGFR2-Akt-eNOS signaling, nitric oxide bioavailability, FAK-paxillin cascade. PMC8275860
⁹ TB-500 prodrug metabolism — TB-500 undergoes serial C-terminal cleavage; metabolite Ac-LKKTE showed significant wound healing activity, suggesting TB-500 functions partly as a prodrug. Yang Y et al. Drug Test Anal. 2024;16(10):1248-1258. PMID 38382158
¹⁰ Meprin-alpha/POP processing cascade — POP cannot cleave full-length TB-4 (exceeds ~30 aa structural limit). Meprin-alpha first cuts TB-4 at multiple sites, producing intermediates that POP then processes to release Ac-SDKP. Kumar N, Bhatt DL. "Meprin β metalloproteases release N-acetyl-seryl-aspartyl-lysyl-proline from thymosin β4." Kidney Int. 2016;89(6):1138-1150. PMC4889319
¹¹ Local concentration matters for therapeutic effect — Free systemic TB-4 at the same total dose as a fibrin-targeted nanoparticle formulation produced no functional improvement in cardiac repair — systemic dilution dropped tissue concentration below therapeutic threshold. Targeted delivery achieved 4× dose reduction while improving all endpoints. Huang G et al. "Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles." Int J Nanomedicine. 2017;12:3023-3036. PMC5396927
¹² Local sustained delivery in diabetic wound healing — TB-4 encapsulated in collagen-chitosan scaffold achieved controlled local release over 12 days; 93% wound closure at day 21 in diabetic rats with hindlimb ischemia. Faster re-epithelialization, organized collagen fibers, significantly increased CD31-positive vessel density (p<0.05). VEGF/AKT pathway activation confirmed. Ti D et al. "Controlled release of thymosin beta 4 using a collagen-chitosan sponge scaffold augments cutaneous wound healing and increases angiogenesis in diabetic rats with hindlimb ischemia." Tissue Eng Part A. 2015;21(3-4):541-549. PMID 25204972
¹³ TB-500 identification and mislabeling documentation — Confirmed TB-500 is Ac-LKKTETQ (N-terminally acetylated fragment 17-23). Acetylation protects N-terminus from aminopeptidase degradation; C-terminus undergoes serial cleavage. Analysis of commercial products found vials labeled "TB-500" containing full-length TB-4. Esposito S et al. "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to be used in horse doping." Drug Test Anal. 2012;4(9):733-738. PMID 22962027
¹⁴ TB-4 biodistribution — Tissue distribution data for synthetic thymosin beta-4 after administration. Mora CA et al. "Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice." Int J Immunopharmacol. 1997;19(1):1-8. PMID 9226473
¹⁵ Fragment-specific activities review — Comprehensive mapping of TB-4 fragment functions: fragment 17-23 (LKKTETQ) drives angiogenesis and cell migration; fragment 1-4 (Ac-SDKP) suppresses NF-kB and reduces fibrosis; fragment 1-15 inhibits caspases 2/3/8/9 (anti-apoptotic). Xing Y et al. "Progress on the Function and Application of Thymosin β4." Front Endocrinol. 2021;12:767785. PMC8724243
Foundational Reviews
¹⁶ Crockford D, Turjman N, et al. "Thymosin beta4: a multi-functional regenerative peptide." Ann N Y Acad Sci. 2017. PMID 28830579
¹⁷ Smart N, Riley PR. "Thymosin beta4 and cardiac repair." Ann N Y Acad Sci. 2012. PMID 22074405
¹⁸ Philp D, Kleinman HK. "Thymosin beta4 promotes dermal healing." Vitam Horm. 2010. PMID 20685922
¹⁹ Sosne G, Qiu P, et al. "Thymosin beta 4 treatment for corneal epithelial wound healing." Ann N Y Acad Sci. 2010. PMID 20016110
²⁰ Bock-Marquette I, Saxena A, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004. PMID 17507482
²¹ Malinda KM, Sidhu GS, et al. "Thymosin beta 4 activates endothelial cells for angiogenesis and wound healing." J Invest Dermatol. 1999. PMID 19714550
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.